Phase I trial of levodopa-deuterated (SD 1077)

Trial Profile

Phase I trial of levodopa-deuterated (SD 1077)

Planning
Phase of Trial: Phase I

Latest Information Update: 05 May 2015

At a glance

  • Drugs Levodopa deuterated (Primary)
  • Indications Movement disorders; Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 27 Jan 2015 New trial record
    • 12 Jan 2015 This trial is expected to be initiated by the end of 2015, with results data reported in 2016, according to an Auspex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top